platelet-derived growth factor
platelet derived growth factor , PDGF (skrót)

It is directed against the platelet-derived growth factor receptor alpha.

Following its purification it has been possible to study the biological properties of platelet-derived growth factor.

The protein encoded by this gene is a member of the platelet-derived growth factor family.

Procuren is a combination of platelet-derived growth factors.

It is also known as "platelet-derived growth factor BB".

The protein, platelet-derived growth factor, is released by the body in response to an injury to the blood vessel, and helps the wound heal.

Human genes encoding proteins that belong to the platelet-derived growth factor family include:

AKT1 and the related AKT2 are activated by platelet-derived growth factor.

Curatech, which markets a platelet-derived growth factor, procuren, to treat wounds, soon outgrew its interim quarters.

The thermos contained a thin clear potion of powerful wound-healing chemicals, platelet-derived growth factors, distilled from her own blood.

However the resulting fusion protein is processed into mature platelet-derived growth factor which is a potent growth factor.

Platelets also secrete platelet-derived growth factor (PDGF).

The translocation fuses the collagen gene (COL1A1) with the platelet-derived growth factor gene.

Platelet-derived growth factor (PDGF)

One of the things that happens when the skin is cut is that blood cells rush to the scene and release a growth protein called platelet-derived growth factor.

It remains to be seen whether cells can respond to platelet-derived growth factor in vivo and, at the moment, its role in atherogenesis remains speculative but attractive.

Platelet-derived growth factor D is a protein that in humans is encoded by the PDGFD gene.

It differs from the platelet-derived growth factor alpha and beta polypeptides in having an unusual N-terminal domain, the CUB domain.

VEGF is a sub-family of growth factors, to be specific, the platelet-derived growth factor family of cystine-knot growth factors.

In molecular biology, platelet-derived growth factor (PDGF) is one of the numerous growth factors, or proteins that regulate cell growth and division.

In addition, the emerging information regarding the properties of the platelet-derived growth factor argues for an important role in the atherogenic process of this platelet α-granule constituent.

The important platelet mitogen, platelet-derived growth factor which is an α-granule constituent along with β-thromboglobulin and platelet factor 4 has been discussed earlier in this chapter.

Many factors promote the growth of MSCs including: platelet-derived growth factor, epidermal growth factor β, and insulin-like growth factor-1.

The first examples of signaling scaffold proteins were receptor tyrosine kinases like epidermal growth factor receptors and platelet-derived growth factor receptor.

SU6656 was initially published as a Src family kinase inhibitor with selectivity relative to Platelet-derived growth factor receptor Tyrosine kinase.

The injection of blood contains small cells called platelets, which contain platelet derived growth factor.

Platelet derived growth factor is a major inducer of CCL2 gene.

Of particular interest to his group is platelet derived growth factor, a substance made by platelets, blood components that are important in the clotting process.

Activators of this pathway include platelet derived growth factor and fibroblast growth factor.

Recent advances have seen the introduction of platelet derived growth factor (PDGF) infused bone graft material.

Gleevec, which is taken in pill form, may also be effective against a third category of more common cancers, ones in which a protein called platelet derived growth factor is active.

One such case is platelet derived growth factor, or PDGF, a substance found originally in platelets, the blood particles that are crucial to the normal process of blood clotting.

It also inhibits the platelet derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR).

This leads to the degredation of HIF1α and prevents the transcription of hypoxic response genes such as vascular endothelial growth factor, platelet derived growth factor B and erythropoietin.

HIF-1α causes the production of vascular endothelial growth factor, platelet derived growth factor B, erythropoietin and transforming growth factor alpha, which act to stimulate growth of cells within the tumour.

The first such discovery, made about four years ago, showed that the product of one oncogene was almost identical to a part of a protein called platelet derived growth factor, that plays a role in normal cell growth.

Most studies have looked at the receptor tyrosine kinases and examples of these are platelet derived growth factor receptor (PDGFR) pathway and epidermal growth factor receptor (EGFR).

These inhibitors include Sunitinib, Pazopanib, Sorafenib, and Axitinib, all of which inhibit platelet derived growth factor receptors (PDGF-Rs) and VEGF receptors (VEGFRs).